CIRIUS THERAPEUTICS
Cirius Therapeutics is a clinical-stage company that develops insulin sensitizer for the treatment of non-alcoholic steatohepatitis. The company developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. Through its novel insulin-sensitizing mechanism of action, MSDC-0602K has the potential to resolve the underlying pathophysiology of NASH. Circius Therapeutics focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases. It was founded in 2015 and is based in Kalamazoo, Michigan, United States.
CIRIUS THERAPEUTICS
Industry:
Biopharma Biotechnology Medical Device Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
Kalamazoo, Michigan, United States
Country:
United States
Website Url:
http://www.ciriustx.com
Total Employee:
11+
Status:
Active
Contact:
(269)343-6732
Total Funding:
49 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics WordPress Google Universal Analytics Mobile Non Scaleable Content Sitelinks Search Box Euro Organization Schema
Similar Organizations
Alios BioPharma
Alios BioPharma is a biotechnology company developing novel medicines for the treatment of viral diseases.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Employees Featured
Jerry Colca Co-founder and Vice President, Research and Development @ Cirius Therapeutics
Co-founder and Vice President, Research and Development
Brian K Farmer Chief Financial Officer and Chief Business Officer @ Cirius Therapeutics
Chief Financial Officer and Chief Business Officer
Robert Baltera CEO @ Cirius Therapeutics
CEO
2017-04-01
Founder
Investors List
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series A - Cirius Therapeutics
Adams Street Partners
Adams Street Partners investment in Series A - Cirius Therapeutics
Novo Holdings
Novo Holdings investment in Series A - Cirius Therapeutics
Hopen Life Science Ventures
Hopen Life Science Ventures investment in Series A - Cirius Therapeutics
Novo Holdings
Novo Holdings investment in Series A - Cirius Therapeutics
Renaissance Venture Capital
Renaissance Venture Capital investment in Series A - Cirius Therapeutics
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series A - Cirius Therapeutics
Adams Street Partners
Adams Street Partners investment in Series A - Cirius Therapeutics
Official Site Inspections
http://www.ciriustx.com Semrush global rank: 8.14 M Semrush visits lastest month: 359
- Host name: a16e665f42988324c.awsglobalaccelerator.com
- IP address: 76.223.105.230
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Cirius Therapeutics"
Team - ciriustx.com
Robert A. Beardsley, PhD Robert A. Beardsley, PhD. Chief Executive Officer. Jerry Colca, Ph.D. Robert A. Beardsley, PhD Robert A. Beardsley, PhDSee details»
Innovative therapies for patients suffering from diseases caused by ...
Azemiglitazone + GLP-1 Lean Muscle Benefit, cardiometabolic benefit to glp-1 receptor agonists, type 2 diabetes, obesity, insulin resistanceSee details»
Al Beardsley - ciriustx.com
Al has over 30 years experience in drug development and company-building, and has served as our Chief Executive Officer since 2024. Prior to joining Cirius, he served in various roles, …See details»
Working At Cirius Therapeutics: Company Overview and Culture
May 18, 2020 ciriustx.com. Organization Type. Private. CEO. Robert F Baltera. Developer of an insulin sensitizer drug designed for the treatment of nonalcoholic liver disease. The company's …See details»
Cirius Therapeutics - Crunchbase Company Profile
Cirius Therapeutics is a clinical-stage company that develops insulin sensitizer for the treatment of non-alcoholic steatohepatitis. The company developing …See details»
Cirius Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Cirius Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 4 news, and 3 literature, Disease Domain ...See details»
Cirius Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Cirius Therapeutics, Inc. of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
Cirius Therapeutics - Overview, News & Similar companies
View Cirius Therapeutics (www.ciriustx.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
MitoWorld
Cirius Therapeutics is a clinical-stage pharmaceutical company focused on the development of innovative therapies for the treatment of liver and metabolic diseases. Cirius is developing MSDC-0602K, a novel, once-daily, oral small …See details»
David VanAndel - ciriustx.com
David Van Andel has served on Cirius’ board of directors since May 2016. Mr. Van Andel is the chairman of the board of directors and chief executive officer of the Van Andel Institute for …See details»
Cirius Therapeutics, Inc. (Cirius Therapeutics, Inc.) - 药物管线_专利_ …
BACKGROUND & AIMS MSDC-0602K is a novel insulin sensitizer designed to preferentially target the mitochondrial pyruvate carrier while minimizing direct binding to the transcriptional …See details»
Cirius Therapeutics - Craft
Kalamazoo, MI HQ. United States. Haymarket Building, 161 E Michigan Ave 4th Floor. San Diego, CA. United States. 12651 High Bluff Dr #150See details»
Cirius Therapeutics Company Profile 2024: Valuation, Funding ...
Cirius Therapeutics General Information Description. Developer of an insulin sensitizer drug designed for the treatment of nonalcoholic liver disease. The company's sensitizer drug is …See details»
Cirius Therapeutics, Inc. in San Diego, CA - (858) 333-6274 - Profile
Cirius Therapeutics, Inc. is in the Physical Therapist business. View competitors, revenue, employees, website and phone number.See details»
Cirix Inc. Company Profile | Oakville, ON, Canada | Competitors ...
Find company research, competitor information, contact details & financial data for Cirix Inc. of Oakville, ON. Get the latest business insights from Dun & Bradstreet.See details»
Jerry Colca, Ph.D. Chief Science Officer - ciriustx.com
Jerry is a widely recognized expert in the pathophysiology of insulin resistance and the pharmacological mechanisms of action of insulin sensitizing drugs.See details»
Cirius Therapeutics to Present Preclinical Data for Lead Drug …
Mar 27, 2019 SAN DIEGO and KALAMAZOO, Mich., March 27, 2019 /PRNewswire/ -- Cirius Therapeutics, a clinical stage pharmaceutical company focused on the development and …See details»
Julie Iwashita | Cirius - ciriustx.com
Julie brings more than 25 years of experience guiding clinical development programs through the U.S. Food and Drug Administration clearance process.See details»
NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular ...
Jan 23, 2020 Jerry Colca Cirius Therapeutics, Kalamazoo, MI, USA;Cirius Therapeutics, San Diago, CA, USA Correspondence jcolca@ciriustx.com View further author information Pages …See details»
Science - ciriustx.com
In a 52-week placebo-controlled Phase 2b (N=392), 0602K markedly improved glycemic control, insulin response, fatty liver and a variety of key metabolic biomarkers, and was well tolerated.See details»